ArticleFrontiers in endocrinology2026
Head-to-head comparison of stress hyperglycemia ratio versus triglyceride-glucose index for predicting mortality in heart failure: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a life-threatening clinical syndrome characterized by high incidence and mortality, leading to considerable global health and economic burdens. Stress-induced hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index, as emerging biomarkers reflecting glucose metabolism, are closely associated with poor prognosis in many diseases. However, it remains unclear which of these two indicators possesses superior association and predictive value for prognosis in critically ill patients with HF. Methods: A retrospective cohort study was conducted on critically ill HF patients, enrolled from the Medical Information Mart for Intensive Care IV (MIMIC-IV) version 3.1. The primary outcome was 180-day mortality, with 1-year (365-day), 90-day, and 30-day mortality as secondary outcomes. Baseline characteristics were compared between survivors and non-survivors. Cox regression, restricted cubic spline (RCS), Kaplan-Meier (K-M), and subgroup analyses were used to assess the association of SHR and TyG index with mortality. Discriminative performance of SHR versus TyG index was compared using ROC curves. Results: A total of 1,063 patients were enrolled. After adjusting for confounders, Cox regression analyses revealed that SHR was significantly associated with an increased risk of 180-day, 365-day, 90-day, and 30-day mortality, with hazard ratios (HRs) of 1.35, 1.26, 1.47, and 1.53, respectively. In contrast, TyG index was only associated with mortality risk at 180, 90, and 30 days (HRs: 1.20, 1.24, and 1.31, respectively), with no significant association observed at 1 year. Moreover, these associations were predominantly linear in nature. However, no statistically significant difference was observed in the predictive performance of SHR and TyG index for mortality at any time points ( Conclusion: SHR and TyG index can be used as potential risk assessment tools for short-term (180-, 90-, and 30-day) mortality risk in critically ill HF patients, nevertheless, SHR is a more applicable and robust metabolic biomarker associated with 1-year mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.